Deep Genomics Exit Candidate

Employees 50+
Primary contact

🏦 Potential exit path: SPAC, M&A
Founded in 2015, Deep Genomics has developed an AI technology designed to help program and prioritize transformational RNA therapeutics for genetic diseases. The Toronto-based company's main program, called the AI Workbench, was designed to help decipher RNA data and in turn pinpoint novel targets for genetically defined diseases. The system uses AI and machine learning to come up with "billions of predictions" related to genetic variants and novel compounds — enabling a new approach to drug development.
Select partners: BioMarin Pharmaceutical.
Employees 50+
Primary contact

Funding πŸ’°

Total $236.4M
Last round πŸ”— $180M
Series C
July 28, 2021.
Select investors SoftBank Vision Fund, Khosla Ventures, True Ventures, Amplitude Venture Capital, Magnetic Ventures, Fidelity Management and Research Company, Alexandria Venture Investments

Key people πŸ§‘β€πŸ€β€πŸ§‘

Highlights ⭐

  • Genomics is a booming sector
  • The success of mRNA-based COVID-19 vaccines have put the RNA-related technologies to the spotlight
  • Could be an attractive target for a major pharmaceutical company looking to benefit from RNA drug development tech
  • Ready to expands partnership with a dedicated person brought on board in November 2020 πŸ”—
Last update: August 11, 2021